<ul data-eligibleForWebStory="false"><li>Hundreds of biotech companies emerge with grand promises but often fail to deliver.</li><li>Investors are more attracted to novelty than sound science, leading to unsustainable valuations.</li><li>Biotech industry prioritizes storytelling over solving real-world problems, losing sight of patient outcomes.</li><li>Call for actionable science, reproducible evidence, and accountability to refocus biotech on innovation.</li><li>It's time for the industry to prioritize clarity, conscience, and patient well-being over capital gains.</li></ul>

The Biotech Bubble: Innovation or Illusion?

Discover more